Metraipolis › archive › dc_e88cb1325df0
Medicare Part D Use and Costs for Immune-Mediated Neurologic Therapies — Europe PMC PMID:41114975
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41114975
- DOI
- 10.1001/jamanetworkopen.2025.38277
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-09T15:52:29.790Z
- SHA-256 of the archived text
daad0303a1cf3166b6d41fc61016d1876a5e7857dd393c18db1d530e9d590388- Stable URL of this page
https://metraipolis.com/documento/dc_e88cb1325df0
How to cite
Medicare Part D Use and Costs for Immune-Mediated Neurologic Therapies — Europe PMC PMID:41114975 — Europe PMC (en), https://europepmc.org/article/MED/41114975 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e88cb1325df0 (Metraipolis archive dc_e88cb1325df0, sha256 daad0303a1cf3166b6d41fc61016d1876a5e7857dd393c18db1d530e9d590388)
BibTeX
@misc{dce88cb1325df0,
title = {Medicare Part D Use and Costs for Immune-Mediated Neurologic Therapies — Europe PMC PMID:41114975},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41114975},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e88cb1325df0; sha256 daad0303a1cf3166b6d41fc61016d1876a5e7857dd393c18db1d530e9d590388},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41114975. Agents can read the archived copy with the MCP tool read_document.